Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Karuna Therapeutics Inc (KRTX)
Karuna Therapeutics Inc (KRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,414,488
  • Shares Outstanding, K 37,727
  • Annual Sales, $ 10,640 K
  • Annual Income, $ -276,340 K
  • 60-Month Beta 1.11
  • Price/Sales 697.05
  • Price/Cash Flow N/A
  • Price/Book 5.60
Trade KRTX with:

Options Overview Details

View History
  • Implied Volatility 54.16% ( +3.81%)
  • Historical Volatility 49.11%
  • IV Percentile 72%
  • IV Rank 57.79%
  • IV High 69.93% on 10/13/23
  • IV Low 32.57% on 06/16/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 206
  • Volume Avg (30-Day) 451
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 10,955
  • Open Int (30-Day) 10,193

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -2.63
  • Number of Estimates 11
  • High Estimate -2.12
  • Low Estimate -3.35
  • Prior Year -2.22
  • Growth Rate Est. (year over year) -18.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
162.46 +21.61%
on 11/10/23
199.37 -0.90%
on 12/04/23
+12.15 (+6.55%)
since 11/03/23
3-Month
158.38 +24.75%
on 10/03/23
199.37 -0.90%
on 12/04/23
+8.87 (+4.70%)
since 09/01/23
52-Week
158.38 +24.75%
on 10/03/23
245.00 -19.36%
on 06/14/23
-39.25 (-16.57%)
since 12/02/22

Most Recent Stories

More News
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1

Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.

ADAP : 0.5286 (-2.51%)
SPRO : 1.2300 (+5.13%)
KRTX : 197.57 (+0.53%)
LSTA : 2.26 (+0.44%)
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 197.57 (+0.53%)
Karuna Therapeutics to Present at Upcoming Investor Conferences

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 197.57 (+0.53%)
3 Biotech Buyout Targets to Watch

The trio all have late-stage therapies with blockbuster potential.

ETNB : 9.05 (+7.74%)
KRTX : 197.57 (+0.53%)
MORF : 24.95 (+2.21%)
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 19.25 (-1.38%)
PRTC.LN : 149.800 (-0.66%)
BIIB : 232.85 (-0.76%)
KRTX : 197.57 (+0.53%)
VOR : 2.1500 (+11.98%)
AKLI : 0.4760 (-2.86%)
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 197.57 (+0.53%)
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological...

KRTX : 197.57 (+0.53%)
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

BIIB : 232.85 (-0.76%)
GILD : 78.34 (+0.89%)
INCY : 54.96 (+1.74%)
ALT : 4.63 (+29.69%)
KRTX : 197.57 (+0.53%)
Karuna Therapeutics to Present at the Stifel 2023 CNS Days

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions,...

KRTX : 197.57 (+0.53%)
Why Shares of Karuna Therapeutics Were Up Wednesday

The clinical-stage biotech announced positive trial results for its lead therapy.

KRTX : 197.57 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's product candidate consists of KarXT, for the treatment of acute...

See More

Key Turning Points

3rd Resistance Point 207.89
2nd Resistance Point 203.63
1st Resistance Point 200.60
Last Price 197.57
1st Support Level 193.31
2nd Support Level 189.05
3rd Support Level 186.02

See More

52-Week High 245.00
Fibonacci 61.8% 211.91
Fibonacci 50% 201.69
Last Price 197.57
Fibonacci 38.2% 191.47
52-Week Low 158.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar